The FDA just approved the Novavax actual vaccine for covid.
It is a real vaccine, cultured in vats, and is not mRNA based.
It has a long success history in other countries.
{...
FDA Panel Backs New COVID Vaccines Aimed at Dominant Strain
— Panelists favored a monovalent XFG-targeted vaccine
by
Kristina Fiore, Director of Enterprise & Investigative Reporting, MedPage Today
May 28, 2026
The FDA's vaccine advisors voted 8 to 0, with one abstention, in favor of a monovalent XFG vaccine for COVID-19 shots for the 2026-2027 season.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) also discussed the need to target the long-simmering
BA.3.2 variant, also known as "cicada," though most expressed confidence that targeting XFG was the right way to go.
"The XFG variant is the most common variant in the U.S. right now, and looking at the other JN.1 variants that may be coming up, I still think that the BA.3.2 variant is not as common. I think we have to keep surveillance very vigilant though," said Anna Durbin, MD, of Johns Hopkins Bloomberg School of Public Health in Baltimore, adding that the "immunogenicity of the vaccines looks good, so I was very comfortable voting yes."
Stanley Perlman, MD, PhD, of the University of Iowa in Iowa City, who chaired the meeting, noted that the
World Health Organization recommended the LP.8.1 strain for next year's vaccines, which "would have been fine," he said. The currently available vaccines from Moderna and Pfizer target LP.8.1.
"I was also really swayed by the fact that Sanofi made the XFG vaccine," Perlman said. "They don't have LP.8.1, and given that the two are very similar, I think that for the U.S., having XFG is a good choice."
Perlman was referring to Sanofi's Nuvaxovid, the protein subunit vaccine acquired from developer Novavax that takes longer to develop and manufacture compared with its sister products, which use mRNA technology.
...}
https://www.medpagetoday.com/infect...&utm_term=NL_Gen_Int_Daily_News_Update_active